Lung Cancer Clinical Trial
Official title:
Development and Feasibility of a Lung Cancer Nurse Model During Early Treatment: a Phase II Study
Lung cancer patients experience significant physical symptoms, psychological distress and
have many supportive care needs that impact on quality of life. Implementing the role of a
Lung Cancer Nurse (LCN) is a response to meet the needs of patients and caregivers.
Primary aim is to assess the feasibility of a LCN intervention and feasibility to collect
longitudinal patient self-assessment questionnaires at the Thoracic Cancer Centre of the
University Hospital of Lausanne.
Secondary aims are: i) to describe self-reported changes in self-efficacy, symptoms and
unmet supportive care needs across three time points during the first line therapy and ii)
to explore professional acceptability of the new LCN model evaluating the perceptions of
barriers and facilitators of the model by the LCN and the other multidisciplinary members of
the comprehensive lung cancer care team.
An exact single-stage (no interim analysis) design will be applied to determine feasibility
for further studies to be undertaken. Secondary outcomes will be analyzed descriptively at
each data collection (Baseline, Time1, Time2) time point and professional acceptability will
be explored by focus groups with selected members of the interdisciplinary team.
To develop adequate self-care strategies, patients with lung cancer and their families are
in need of emotional, informational and behavioural supportive care. Supportive care in
cancer can reduce symptom burden and improve patients and their families self-management
skills. As lung cancer incidence continues to rise, and increased attention is given to
early diagnosis, research on early involvement of lung cancer nurse (LCN) in care, the
feasibility and impact on patient outcomes is needed.
Primary aim is to assess the feasibility of a LCN intervention and feasibility to collect
longitudinal (Baseline, Time1, Time2) patient self-assessment questionnaires at the Thoracic
Cancer Centre of the University Hospital of Lausanne.
Secondary aims are: i) to describe self-reported changes in self-efficacy, symptoms and
unmet supportive care needs across three time points during the first line therapy and ii)
to explore professional acceptability of the new LCN model evaluating the perceptions of
barriers and facilitators of the model by the LCN and the other multidisciplinary members of
the comprehensive lung cancer care team.
An exact single-stage (no interim analysis) design will be applied to determine feasibility
for further studies to be undertaken. Lung cancer patients with planned systemic therapy
with or without radiotherapy will be recruited at the thoracic cancer center in a Swiss
University Hospital. The LCN model of care consists of two face-to-face consultations
alternating with two telephone consultations during systemic therapy. LCN consultations will
comprise focused assessment of physical and psychological symptoms, information (printed and
oral) about disease and its treatment, therapeutic education concerning strategies to manage
physical and psychosocial symptoms and review of available support resources. Participants
will be invited to complete the validated patient reported Lung Cancer Symptom Scale,
Supportive Care Needs Screening Tool 9 and Self-Efficacy Scale for Lung Cancer. Study data
will be collected at baseline (day 1 of systemic therapy), time 1 (week 3 of systemic
therapy) and time 2 (week 11 of systemic therapy). Participants will be categorized as
adherent if they complete all their scheduled LCN consultations and questionnaires. For a 5%
probability of accepting a poor feasibility (alpha) and a 20% probability of rejecting an
acceptable feasibility (beta) we then need to enroll 71 patients. Feasibility will be
considered as acceptable for further studies if at least 36 patients will be compliant.
Secondary outcomes will be analyzed descriptively for each variable (self-efficacy, symptoms
and supportive care needs) across each time point. At the end of quantitative data
collection, a focus group will be conducted to explore acceptability of the new role among
health professionals working with the LCN in order to identify perceived barriers and
facilitators for collaborative work with the new role.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|